Lentiviral vectors (LVV) have significant potential for cell and gene therapy. This approach to engineer T-cells using chimeric antigen receptors (CAR-T) or cloned T-cell receptors (TCR) is proving successful for treatment of B-cell malignancies for which current chemotherapies are highly ineffective. However, challenges remain with the manufacturing process, such as robustness, scalability and high costs, ultimately resulting in a burden for the healthcare system and individual patients. Our aim is to develop a technology that reduces the several challenges of LVV manufacture to allow these therapies to become more available to patients in need.
Download the resource to continue reading.